Health · 4 views
Immunotherapy combo extends survival for patients with aggressive small cell lung cancer, based on trial results
In patients with extensive-stage small cell lung cancer (ES-SCLC), tarlatamab, a bispecific T-cell engager, plus durvalumab as first-line maintenance therapy extended median overall survival by more than eight months, more than tripled…
AI Summary
In a phase 3 open‑label trial (DeLLphi‑305), patients with extensive‑stage small cell lung cancer received tarlatamab, a bispecific T‑cell engager, together with durvalumab as first‑line maintenance therapy. The combination extended median overall survival by more than eight months, more than tripled progression‑free survival and cut the risk of death by 58% versus durvalumab alone. Benefits were observed across subgroups, including those with brain and liver metastases. Results were presented by Jacob Sands, M.D., at the ESMO Congress 2026 in Madrid on Oct. 24.
AI summaries can be wrong sometimes—always verify important details using the source article.
How AI & Automation are usedMore from Health
Continue reading recent Health coverage
- NHS consultants to go on two-day strike in England in NovemberContinue reading
- Bigger does not always mean better in hospital care | LetterContinue reading
- Why do people still get polio in some countries and not in others?Continue reading
- ‘What’s the safest way to defrost chicken?’ We’re answering your food safety questionsContinue reading
Support HappeningNow
Independent AI-powered news analysis is reader-supported. Your contribution helps cover infrastructure, summaries, and continued platform development.
Support HappeningNow